Table 3.
Pharmacological compounds used in the therapy of chronic obstructive pulmonary disease
| Pharmacological group and its abbreviation | Compounds belonging to the group |
|---|---|
| Short-acting β2-agonists | Salbutamol Terbutaline |
| Long-acting β2-agonist (LABA) | Formoterol Indacaterol Olodaterol Salmeterol Vilanterol |
| Short-acting anticholinergic | Ipratropium |
| Long-acting anticholinergic (LAMA) | Aclidinium Glycopyrronium Tiotropium Umeclidinium |
| Inhaled glucocorticoids (ICS) | Beclomethasone dipropionate Budesonide Ciclesonide Fluticasone propionate Fluticasone furoate Mometasone |
| Fixed combination of inhaled glucocorticoid and long-acting β2-agonist (ICS + LABA) | Budesonide–formoterol Beclomethasone dipropionate–formoterol Fluticasone propionate–salmeterol Fluticasone furoate–vilanterol |
| Fixed combination of long-acting anticholinergic and long-acting β2-agonist (LAMA + LABA) | Glycopyrronium–indacaterol Umeclidinium–vilanterol |
| Phosphodiesterase 4 (PDE4) inhibitors | Roflumilast |
| Others | Theophylline |